Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma L Turner

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Eukaryotic Cell|August 17, 2010
The Saccharomyces cerevisiae anaphase-promoting complex interacts with multiple histone-modifying enzymes to regulate cell cycle progressionEmma L Turner, Mackenzie E Malo, Marnie G Pisclevich, et al.
International Journal of Cancer|May 18, 2010
Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study)Emma L Turner, Janet Athene Lane, Jenny L Donovan, et al.
BMC Health Services Research|June 9, 2023
Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Eleanor I Walsh, et al.
Cancer Causes & Control : CCC|November 11, 2016
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?Sean Harrison, Kate Tilling, Emma L Turner, et al.
BMJ (Clinical Research Ed.)|November 17, 2007
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trialJ Athene Lane, Joanne Howson, Jenny L Donovan, et al.
Journal of Medical Screening|September 5, 2022
Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testingSherena D Jackson, May R de la Rue, Thomas Pl Greenslade, et al.
BMJ Open|November 16, 2017
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)Samuel William David Merriel, Emma L Turner, Eleanor Walsh, et al.
BMJ Open|May 1, 2016
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Luke Hounsome, et al.
Cancer Causes & Control : CCC|March 13, 2020
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigenSean Harrison, Kate Tilling, Emma L Turner, et al.
Pharmacoeconomics|October 6, 2022
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP TrialEdna Keeney, Sabina Sanghera, Richard M Martin, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Eukaryotic Cell|August 17, 2010
The Saccharomyces cerevisiae anaphase-promoting complex interacts with multiple histone-modifying enzymes to regulate cell cycle progressionEmma L Turner, Mackenzie E Malo, Marnie G Pisclevich, et al.
International Journal of Cancer|May 18, 2010
Association of diabetes mellitus with prostate cancer: nested case-control study (Prostate testing for cancer and treatment study)Emma L Turner, Janet Athene Lane, Jenny L Donovan, et al.
BMC Health Services Research|June 9, 2023
Impact of PSA testing on secondary care costs in England and Wales: estimates from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Eleanor I Walsh, et al.
Cancer Causes & Control : CCC|November 11, 2016
Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful?Sean Harrison, Kate Tilling, Emma L Turner, et al.
BMJ (Clinical Research Ed.)|November 17, 2007
Detection of prostate cancer in unselected young men: prospective cohort nested within a randomised controlled trialJ Athene Lane, Joanne Howson, Jenny L Donovan, et al.
Journal of Medical Screening|September 5, 2022
Screening asymptomatic men for prostate cancer: A comparison of international guidelines on prostate-specific antigen testingSherena D Jackson, May R de la Rue, Thomas Pl Greenslade, et al.
BMJ Open|November 16, 2017
Cross-sectional study evaluating data quality of the National Cancer Registration and Analysis Service (NCRAS) prostate cancer registry data using the Cluster randomised trial of PSA testing for Prostate cancer (CAP)Samuel William David Merriel, Emma L Turner, Eleanor Walsh, et al.
BMJ Open|May 1, 2016
Validating the use of Hospital Episode Statistics data and comparison of costing methodologies for economic evaluation: an end-of-life case study from the Cluster randomised triAl of PSA testing for Prostate cancer (CAP)Joanna C Thorn, Emma L Turner, Luke Hounsome, et al.
Cancer Causes & Control : CCC|March 13, 2020
Systematic review and meta-analysis of the associations between body mass index, prostate cancer, advanced prostate cancer, and prostate-specific antigenSean Harrison, Kate Tilling, Emma L Turner, et al.
Pharmacoeconomics|October 6, 2022
Cost-Effectiveness Analysis of Prostate Cancer Screening in the UK: A Decision Model Analysis Based on the CAP TrialEdna Keeney, Sabina Sanghera, Richard M Martin, et al.
Pageof 5